Suchergebnisse - "Rejeski, Kai"

PubPharm (64)

11

Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells

enthalten in: Neuro-oncology | 2023

von Karschnia, P. | Arrillaga-Romany, I. | Eichler, A. | +24

12

Recognizing, defining, and managing CAR-T hematologic toxicities

enthalten in: Hematology. American Society of Hematology. Education Program | 2023

von Rejeski, K. | Subklewe, M. | Locke, F.

13

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

enthalten in: American journal of hematology | 2023

von Rejeski, K. | Wang, Y. | Albanyan, O. | +17

14

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

enthalten in: Blood advances | 2023

von Blumenberg, V. | Busch, G. | Baumann, S. | +24

15

Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2023

von Kampouri, E. | Little, J. | Rejeski, K. | +3

16

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy

enthalten in: Journal for immunotherapy of cancer | 2023

von Winkelmann, M. | Blumenberg, V. | Rejeski, K. | +11

17

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

enthalten in: Blood | 2023

von Karschnia, P. | Miller, K. | Yee, A. | +5

CommentIn: Blood. 2023 Oct 5;142(14):1181-1183. - PMID 37796518

18

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement : a GLA/DRST study

enthalten in: Blood advances | 2023

von Ayuk, F. | Gagelmann, N. | von Tresckow, B. | +8

19

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

enthalten in: Science advances | 2023

von Rejeski, K. | Perez, A. | Iacoboni, G. | +23

20

Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy

enthalten in: Cytotherapy | 2023

von Winkelmann, M. | Blumenberg, V. | Rejeski, K. | +11